GENABLE TECHNOLOGIES LIMITED MOVING GT038 INTO FULL DEVELOPMENT
Dublin, September 2014 - The Genable team recently attended a Pre-IND meeting with the Food and Drug Administration (FDA) in Washington USA, to discuss the development of GT038 for the treatment of Rhodopsin linked autosomal dominant retinitis pigmentosa (Rho-AdRP). It was a very informative meeting during which the FDA provided feedback and advice on the preclinical and clinical development plans for GT038.
Dr Jason Loveridge Genable CEO commented “ Following a very informative and useful meeting with the US medicines regulatory authority, the FDA, we are delighted to confirm that GT038 has now moved from research to development. The FDA’s input taken together with advice from our Medical Advisory Board and most importantly Genable’s close links with patient groups increases the probability that we can progress GT038 into the clinic and subsequently provide benefit for RP patients. |
